Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5474220 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL5460016 | 0.89 | ALDH1A1 (0.39) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL6220387 | 0.89 | KCNA5 (0.39) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL6218371 | 0.86 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL6220580 | 0.86 | ALDH1A1 (0.44) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL5462253 | 0.85 | THRB (0.40) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL5460021 | 0.85 | THRB (0.40) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL5463877 | 0.85 | RAB9A (0.39) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL5455073 | 0.84 | MAPK1 (0.43) | ALDH1A1HPGDMAPK1MEN1KMT2A | |
| SCHEMBL14491863 | 0.78 | KCNA3 (0.58) | ALDH1A1MEN1KMT2AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | ALDH1A1 4075/4885HPGD 3115/4885MAPK1 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.